CHF291.60
1.07% today
SIX Swiss Exchange, Oct 08, 12:43 pm CET
ISIN
CH0012032048
Symbol
ROG
Index

Roche Stock price

CHF288.50
+18.40 6.81% 1M
+42.40 17.23% 6M
+33.00 12.92% YTD
+28.40 10.92% 1Y
-36.00 11.09% 3Y
-24.95 7.96% 5Y
+38.00 15.17% 10Y
+103.30 55.78% 20Y
SIX Swiss Exchange, Closing price Tue, Oct 07 2025
+0.10 0.03%
ISIN
CH0012032048
Symbol
ROG
Index
Industry

Key metrics

Basic
Market capitalization
CHF231.3b
Enterprise Value
CHF248.6b
Net debt
CHF17.3b
Cash
CHF17.3b
Shares outstanding
795.4m
Valuation (TTM | estimate)
P/E
28.0 | 14.5
P/S
3.8 | 3.7
EV/Sales
4.1 | 3.9
EV/FCF
16.5
P/B
7.3
Dividends
DPS
CHF9.70
Yield 1Y | 5Y
3.4% | 3.1%
Growth 1Y | 5Y
1.0% | 1.5%
Payout 1Y | 3Y
94.0% | 72.0%
Increased
25 Years
Financials (TTM | estimate)
Revenue
CHF60.5b | CHF63.3b
EBITDA
CHF20.4b | CHF25.1b
EBIT
CHF20.1b | CHF21.5b
Net Income
CHF8.3b | CHF15.9b
Free Cash Flow
CHF15.1b
Growth (TTM | estimate)
Revenue
3.0% | 4.6%
EBITDA
8.3% | 22.8%
EBIT
8.4% | 7.2%
Net Income
-28.0% | 91.6%
Free Cash Flow
31.8%
Margin (TTM | estimate)
Gross
73.9%
EBITDA
33.8% | 39.7%
EBIT
33.2%
Net
13.7% | 25.1%
Free Cash Flow
24.9%
Financial Health
Equity Ratio
31.2%
Return on Equity
26.1%
ROCE
26.9%
ROIC
25.5%
Debt/Equity
1.1
More
EPS
CHF10.3
FCF per Share
CHF19.0
Short interest
-
Employees
103k
Rev per Employee
CHF590.0k
Show more

Create a Free Account to create an Roche alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Roche Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Roche forecast:

12x Buy
46%
8x Hold
31%
6x Sell
23%

Analyst Opinions

26 Analysts have issued a Roche forecast:

Buy
46%
Hold
31%
Sell
23%

Financial data from Roche

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
60,495 60,495
3% 3%
100%
- Direct Costs 15,783 15,783
1% 1%
26%
44,712 44,712
4% 4%
74%
- Selling and Administrative Expenses 13,758 13,758
2% 2%
23%
- Research and Development Expense 13,042 13,042
1% 1%
22%
20,438 20,438
8% 8%
34%
- Depreciation and Amortization 351 351
4% 4%
1%
EBIT (Operating Income) EBIT 20,087 20,087
8% 8%
33%
Net Profit 8,277 8,277
28% 28%
14%

In millions CHF.

Don't miss a Thing! We will send you all news about Roche directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Roche Stock News

Neutral
Business Wire
one day ago
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of 89bio, Inc. (NasdaqGM: ETNB) to Roche Holding AG (OTC: RHHBY). Under the terms of the proposed transaction, shareholders of 89bio will receive $14.50 per share in cash at closing, plus a non-tradea...
Positive
Seeking Alpha
one day ago
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their po...
Neutral
GlobeNewsWire
2 days ago
Basel, 6 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY), in collaboration with KlinRisk, Inc., has received the CE-mark for the first AI-based risk stratification tool to assess progressive decline in kidney function. This milestone allows Roche to introduce the Chronic Kidney Disease (CKD) algorithm panel on its navify® Algorithm Suite to support care across all stages of the CKD care pathw...
More Roche News

Company Profile

Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Head office Switzerland
CEO Thomas Schinecker
Employees 103,249
Founded 1896
Website www.roche.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today